News & Events

News

Nexstim offers targeted and effective therapies and diagnostics for challenging brain diseases and disorders. Our technology is solidly grounded in scientific and clinical research. We closely collaborate with key opinion leaders who, like us, believe noninvasive brain stimulation harnesses the brain's own healing power—neuroplasticity. Nexstim is helping patients—and their families—get back the life they feared they had lost.

Customers and Trade

Research and Development

Nexstim Plc receives R&D loan from Business Finland

Nexstim enrols last patient in supplementary Phase III E-FIT trial

Issuance of shares pursuant to the restricted share unit reward plan

Nexstim Plc’s Financial Information in 2018

Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting

Nexstim Plc Appoints Steve Beller as Vice President and General Manager, North America

Nexstim gains FDA clearance to commercialise its NBT® system in the US for the treatment of depression

Nexstim raises EUR 1.75 million via a directed issue of new shares to London-based investor City Financial – Funds to be used to support beginning the commercialisation of its NBT® system

The Board of Directors of Nexstim Plc resolved on amendments of the stock options 2016 and on a new stock option plan for the CEO

Nexstim Plc is negotiating an assembly and distribution arrangement in China and a financing arrangement for the financing of its bring-to-market strategy in Europe and the US

Change in Nexstim Plc's Management Team

Change in Nexstim Plc's Management Team